Absolute Antibody Increases Automation Capabilities and Expands Production Facility to Support Continued Growth of its Recombinant Antibody Technology

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, announced the near doubling of its manufacturing facility in northeast England. The increased laboratory space includes a major investment in new automation for Next Generation Sequencing (NGS), expression and purification (HPLC) to enhance recombinant antibody production workflows. The additional space and equipment will enable Absolute Antibody to better service customers and accelerate the expansion of its recombinant antibody portfolio.

“The increased space and automation is a direct result of the continued growth of our company and underlines our commitment to our clients and to advancing recombinant antibody technology,” said Dr. Ed Horton, Chief Commercial Officer of Absolute Antibody. “We are excited to leverage our increased production capacity and additional automation capabilities to serve new and existing customers more efficiently and respond to the growing demand for recombinant antibodies across a variety of applications.”

Recommended AI News: ITsavvy Announces Acquisition of Technology Resource Advisors K-12 Computing

The facility is ISO-certified and located at the Wilton Centre in Redcar, England, where Absolute Antibody has based its research and manufacturing since 2014. The upgraded space includes additional manufacturing lines and state-of-the-art robotics to increase efficiency and enable the completion of larger and higher volume projects. The new labs will also accommodate additional scientific staff members to support company growth, while still providing the highest quality antibody services and products.

Absolute Antibody’s facility expansion follows its recent acquisition by LSBio, which provides clients with a larger portfolio of antibody-related products and services. The combined company is focused on increasing the availability of highly defined recombinant antibodies, which offer ensured reproducibility, an animal-free manufacturing process, and the ability to engineer antibodies into any species, isotype or format.

Since its founding in 2012, Absolute Antibody has grown rapidly. The company’s custom antibody sequencing, engineering and expression services are used by leading pharmaceutical, biotechnology and diagnostics companies, as well as by academic researchers worldwide. Its reagents catalog offers a wide range of recombinant antibodies in new engineered formats, absolutely defined at the amino acid level to ensure batch-to-batch reproducibility.

Recommended AI News: New Arizent Research, the Future of the Data-Driven Workplace, Analyzes Artificial Intelligence Implementation in Financial Services and the Benefits It Provides

[To share your insights with us, please write to sghosh@martechseries.com]